Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review

André D Sasse1*, Elisa Sasse2, Albertina M Carvalho3 and Ligia T Macedo1

Author affiliations

1 Center for Evidences in Oncology, Clinical Oncology Service, Internal Medicine Department Faculty of Medical Sciences, University of Campinas--UNICAMP, 6111, 13083-970 Campinas, SP, Brazil

2 Medical School, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

3 Oncology Center (Centro Oncologico), Luanda, Angola

For all author emails, please log on.

Citation and License

BMC Cancer 2012, 12:54  doi:10.1186/1471-2407-12-54

Published: 2 February 2012

Abstract

Background

Locally advanced prostate cancer is often associated with elevated recurrence rates. Despite the modest response observed, external-beam radiotherapy has been the preferred treatment for this condition. More recent evidence from randomised trials has demonstrated clinical benefit with the combined use of androgen suppression in such cases. The aim of this meta-analysis is to compare the combination of distinct hormone therapy modalities versus radiotherapy alone for overall survival, disease-free survival and toxicity.

Methods

Databases (MEDLINE, EMBASE, LILACS, Cochrane databases and ClinicalTrials.gov) were scanned for randomised clinical trials involving radiotherapy with or without androgen suppression in local prostate cancer. The search strategy included articles published until October 2011. The studies were examined and the data of interest were plotted for meta-analysis. Survival outcomes were reported as a hazard ratio with corresponding 95% confidence intervals.

Results

Data from ten trials published from 1988 to 2011 were included, comprising 6555 patients. There was a statistically significant advantage to the use of androgen suppression, in terms of both overall survival and disease free survival, when compared to radiotherapy alone. The use of long-term goserelin (up to three years) was the strategy providing the higher magnitude of clinical benefit. In contrast to goserelin, there were no trials evaluating the use of other luteinizing hormone-releasing hormone (LHRH) analogues as monotherapy. Complete hormonal blockade was not shown to be superior to goserelin monotherapy.

Conclusions

Based on the findings of this systematic review, the evidence supports the use of androgen suppression with goserelin monotherapy as the standard treatment for patients with prostate cancer treated with radiotherapy, which are at high risk of recurrence or metastases.